Category: Federal Forum Posters
Purpose: Second generation antipsychotics (SGAs) are associated with metabolic complications including glucose intolerance, weight gain, and hyperlipidemia. Such metabolic factors contribute to the development of cardiovascular disease and increase a patient’s risk of cardiovascular mortality. Guidelines recommend metabolic monitoring for patients taking SGAs to allow for early detection of metabolic abnormalities and subsequent interventions. The purpose of this medication use evaluation is to describe and assess metabolic monitoring patterns for SGAs within a healthcare system.
Methods: The investigation of metabolic monitoring practices will be conducted through a retrospective chart review. Patients included in this evaluation will be enrolled in a mental health intensive case management (MHICM) patient group and prescribed scheduled SGAs. The following information will be collected for each patient: patient characteristics, metabolic monitoring history, and interventions implemented to address metabolic abnormalities. Measures of body mass index, waist circumference, blood pressure, fasting plasma glucose, and fasting lipids will be used as data points for metabolic monitoring history. Pharmacologic interventions include statins, antidiabetic agents, and antihypertensive agents. Nonpharmacologic interventions consist of referrals to weight management programs, nutrition consults, and diabetic education consults. The primary outcome measured will be the percentage of patients appropriately receiving metabolic monitoring at guideline-directed intervals and the secondary outcome will be the percentage of patients who have pharmacologic or non-pharmacologic interventions documented in response to abnormal metabolic measures.
Results: Not applicable
Conclusion: Not applicable
Ruby Gale– Pharm.D. Candidate 2018, University of Montana, Missoula, MT